Potential Long-Term Cost Savings Due to Significant Clinical Benefit of Obinutuzumab (Ga101) in Combination with Chlorambucil in Previously Untreated Chronic Lymphocytic Leukemia
Abstract
Authors
S. Walzer C. Tournier J.P. Marino E. Mueller M. Duong